|
EP0326364B1
(fr)
*
|
1988-01-26 |
1994-06-22 |
Sankyo Company Limited |
Polypeptide inhibant la rénine, sa fabrication et son utilisation
|
|
US5238923A
(en)
*
|
1989-05-26 |
1993-08-24 |
Warner-Lambert Company |
Amino-substituted heterocycles as renin inhibitors
|
|
IE68045B1
(en)
*
|
1990-05-11 |
1996-05-15 |
Abbott Lab |
Renin inhibitors
|
|
WO1993006127A1
(fr)
*
|
1991-09-17 |
1993-04-01 |
Warner-Lambert Company |
Nouveaux inhibiteurs de renine a base de promedicaments a acides amines
|
|
US5223535A
(en)
*
|
1991-10-29 |
1993-06-29 |
G. D. Searle & Co. |
Propargyl glycine amino propargyl diol compounds for treatment of hypertension
|
|
EP0539976A1
(fr)
*
|
1991-10-29 |
1993-05-05 |
G.D. Searle & Co. |
Dérivés d'éthynyl alanine amino diol pour le traitement de l'hypertension
|
|
US5227401A
(en)
*
|
1991-10-29 |
1993-07-13 |
G. D. Searle & Co. |
Ethynyl alanine amino diol compounds for treatment of hypertension
|
|
NZ249022A
(en)
*
|
1992-02-13 |
1996-06-25 |
Warner Lambert Co |
Preparation of (-)-(s)- and (+)-(r)- ethyl (5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido[3,4-b]pyrazin-7 -yl) carbamate; pyridyl amino hydroxamic acid precursors
|
|
US5972990A
(en)
*
|
1992-04-10 |
1999-10-26 |
Brigham And Women's Hospital, Inc. |
Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
|
|
US5298505A
(en)
*
|
1992-08-14 |
1994-03-29 |
G. D. Searle & Co. |
Ethynyl alanine amino diol compounds having a piperazinyl-terminated group or a piperazinyl-alkylamino-terminated group for treatment of hypertension
|
|
US5373017A
(en)
*
|
1992-08-14 |
1994-12-13 |
G. D. Searle & Co. |
Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension
|
|
US5252591A
(en)
|
1992-08-14 |
1993-10-12 |
G. D. Searle & Company |
Pyridinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension
|
|
US6376506B1
(en)
|
1997-01-23 |
2002-04-23 |
Syntex (U.S.A.) Llc |
Sulfamide-metalloprotease inhibitors
|
|
ZA98376B
(en)
*
|
1997-01-23 |
1998-07-23 |
Hoffmann La Roche |
Sulfamide-metalloprotease inhibitors
|
|
EP1012839A4
(fr)
*
|
1997-04-30 |
2001-01-10 |
Spectra Logic Corp |
Systeme de bibliotheque a chargeur de donnees
|
|
US6423688B1
(en)
*
|
1997-07-31 |
2002-07-23 |
Athena Neurosciences, Inc. |
Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
|
|
US6130220A
(en)
*
|
1997-10-16 |
2000-10-10 |
Syntex (Usa) Inc. |
Sulfamide-metalloprotease inhibitors
|
|
US6407124B1
(en)
|
1998-06-18 |
2002-06-18 |
Bristol-Myers Squibb Company |
Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
|
|
US6410746B1
(en)
*
|
1999-04-27 |
2002-06-25 |
Research Foundation Of State University Of New York, The |
Metal cataltsts and methods for making and using same
|
|
WO2002048715A2
(fr)
|
2000-12-14 |
2002-06-20 |
The Brigham And Women's Hospital, Inc. |
Marqueurs inflammatoires comme outils de detection et de prevention du diabete sucre et comme outils facilitant la selection d'agents s'utilisant dans la prevention et le traitement du diabete
|
|
US7030051B2
(en)
|
2001-08-27 |
2006-04-18 |
The Research Foundation Of State University Of New York |
Dirhodium catalyst compositions and methods for using same
|
|
WO2003018184A2
(fr)
|
2001-08-27 |
2003-03-06 |
The Research Foundation Of State University Of New York |
Compositions catalytiques de dirhodium a support solide et procedes de production et d'utilisation de ces dernieres
|
|
DK3072978T3
(en)
|
2002-05-09 |
2018-09-17 |
Brigham & Womens Hospital Inc |
: 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
|
|
AU2003229016A1
(en)
*
|
2002-05-10 |
2003-11-11 |
The Trustees Of Columbia University In The City Of New York |
Genetically engineered cell lines and systems for propagatingvaricella zoster virus and methods of use thereof
|
|
JP2007502831A
(ja)
*
|
2003-08-20 |
2007-02-15 |
ニトロメッド インコーポレーティッド |
ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
|
|
CA2536975A1
(fr)
*
|
2003-08-28 |
2005-03-17 |
Nitromed, Inc. |
Composes diuretiques nitroses et nitrosyles, compositions et procedes d'utilisation correspondants
|
|
SI2384753T1
(sl)
|
2003-08-29 |
2016-06-30 |
The Brigham And Women's Hospital, Inc. |
Hidantoinski derivati kot inhibitorji celične nekroze
|
|
EP2306192B1
(fr)
|
2003-12-05 |
2015-10-14 |
The Cleveland Clinic Foundation |
Marqueurs de risque pour maladies cardiovasculaires
|
|
CA2554716A1
(fr)
*
|
2004-01-22 |
2005-08-04 |
Nitromed, Inc. |
Composes nitroses et/ou nitrosyles, compositions et procede pour les utiliser
|
|
US7803838B2
(en)
*
|
2004-06-04 |
2010-09-28 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
|
US8067464B2
(en)
|
2004-10-04 |
2011-11-29 |
Nitromed, Inc. |
Compositions and methods using apocynin compounds and nitric oxide donors
|
|
US9164104B2
(en)
|
2004-10-06 |
2015-10-20 |
The Brigham And Women's Hospital, Inc. |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
|
CA2574535A1
(fr)
*
|
2004-11-15 |
2006-05-26 |
Nitromed, Inc. |
Composes diuretiques comprenant des groupes donneurs d'oxyde nitrique heterocycliques, compositions et methodes d'utilisation
|
|
US20080306041A1
(en)
*
|
2005-01-21 |
2008-12-11 |
Garvey David S |
Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use
|
|
WO2006083779A2
(fr)
*
|
2005-01-31 |
2006-08-10 |
Mylan Laboratories, Inc. |
Metabolites de nebivolol hydroxyles
|
|
EP1858525A2
(fr)
*
|
2005-02-16 |
2007-11-28 |
Nitromed, Inc. |
Sels donneurs d oxyde nitrique organique de composes antimicrobiens et composes et procedes d utilisation
|
|
JP2008531697A
(ja)
*
|
2005-02-28 |
2008-08-14 |
ニトロメッド インコーポレーティッド |
酸化窒素増強基を含む心血管化合物、組成物および使用法
|
|
CA2597444A1
(fr)
*
|
2005-03-09 |
2006-09-21 |
Nitromed, Inc. |
Sels organiques d'antagonistes de l'angiotensine ii augmentant le taux de monoxyde d'azote endogene, compositions et procedes d'utilisation correspondants
|
|
AP2896A
(en)
|
2005-05-31 |
2014-05-31 |
Mylan Lab Inc |
Compositions comprising nebivolol
|
|
US7700798B1
(en)
|
2005-06-08 |
2010-04-20 |
The Research Foundation Of State University Of New York |
Erogorgiaene congeners and methods and intermediates useful in the preparation of same
|
|
US7816536B2
(en)
*
|
2005-06-10 |
2010-10-19 |
The Research Foundation Of State University Of New York |
4-substituted and 7-substituted indoles, benzofurans, benzothiophenes, benzimidazoles, benzoxazoles, and benzothiazoles and methods for making same
|
|
WO2007016677A2
(fr)
|
2005-08-02 |
2007-02-08 |
Nitromed, Inc. |
Composes antimicrobiens promoteurs d'oxyde nitrique, compositions et procedes d'utilisation
|
|
WO2007041681A2
(fr)
*
|
2005-10-04 |
2007-04-12 |
Nitromed, Inc. |
Méthodes de traitement de troubles respiratoires
|
|
US8119358B2
(en)
*
|
2005-10-11 |
2012-02-21 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
|
US7838023B2
(en)
*
|
2005-11-16 |
2010-11-23 |
Nitromed, Inc. |
Furoxan compounds, compositions and methods of use
|
|
US7385064B1
(en)
|
2005-11-30 |
2008-06-10 |
The Research Foundation Of State University Of New York |
Catalysts for use in enantioselective synthesis
|
|
WO2007075542A2
(fr)
*
|
2005-12-22 |
2007-07-05 |
Nitromed, Inc. |
Composes au pyruvate activateurs d'oxyde nitrique, compositions et procedes d'utilisation
|
|
EP2302395B1
(fr)
|
2006-06-07 |
2015-04-15 |
Health Diagnostic Laboratory, Inc. |
Marqueurs associés aux événements artériovasculaires et procédés d'utilisation correspondants
|
|
CA2668744C
(fr)
|
2006-11-17 |
2015-09-15 |
Queen's University At Kingston |
Composes et procedes pour traiter des troubles de repliement de proteine
|
|
TW200849035A
(en)
|
2007-04-18 |
2008-12-16 |
Tethys Bioscience Inc |
Diabetes-related biomarkers and methods of use thereof
|
|
US7828840B2
(en)
*
|
2007-11-15 |
2010-11-09 |
Med Institute, Inc. |
Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
|
|
AU2009322836B2
(en)
|
2008-11-25 |
2013-04-04 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
|
AU2009322613A1
(en)
|
2008-12-05 |
2011-06-23 |
Merck Sharp & Dohme Corp. |
Nitrooxy derivatives as angiotensin II receptor antagonists
|
|
JP5075145B2
(ja)
|
2009-02-13 |
2012-11-14 |
トヨタ自動車株式会社 |
内燃機関の制御装置
|
|
CN102414194A
(zh)
|
2009-02-26 |
2012-04-11 |
默沙东公司 |
可溶性鸟苷酸环化酶激活剂
|
|
TW201201764A
(en)
|
2010-02-01 |
2012-01-16 |
Hospital For Sick Children |
Remote ischemic conditioning for treatment and prevention of restenosis
|
|
KR20130040851A
(ko)
|
2010-03-31 |
2013-04-24 |
더 호스피탈 포 식 칠드런 |
심근 경색 후 결과를 개선시키기 위한 원격 허혈 처치의 사용
|
|
WO2011146371A1
(fr)
|
2010-05-21 |
2011-11-24 |
Merck Sharp & Dohme Corp. |
Dérivés cyclohexyliques de diolate de diazénium
|
|
US9108920B2
(en)
|
2010-10-29 |
2015-08-18 |
Merck Sharp & Dohme Corp. |
Diazeniumdiolate heterocyclic derivatives
|
|
RU2598842C2
(ru)
|
2011-01-20 |
2016-09-27 |
Мерк Шарп Энд Домэ Корп. |
Антагонисты рецептора минералокортикоидов
|
|
JO3350B1
(ar)
|
2011-03-07 |
2019-03-13 |
Merck Sharp & Dohme |
مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
|
|
WO2012139495A1
(fr)
|
2011-04-13 |
2012-10-18 |
Merck Sharp & Dohme Corp. |
Antagonistes des récepteurs de minéralocorticoïdes
|
|
CA2832996C
(fr)
|
2011-04-26 |
2019-05-07 |
Merck Sharp & Dohme Corp. |
Composes triazoles tricycliques et leur utilisation comme inhibiteurs d'aldosterone synthase
|
|
US9272987B2
(en)
|
2011-05-02 |
2016-03-01 |
Merck Sharp & Dohme Corp. |
Diazeniumdiolate cyclohexyl derivatives
|
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
|
EP2773206B1
(fr)
|
2011-10-31 |
2018-02-21 |
Merck Sharp & Dohme Corp. |
Inhibiteurs du canal potassique médullaire externe rénal
|
|
WO2013066714A1
(fr)
|
2011-10-31 |
2013-05-10 |
Merck Sharp & Dohme Corp. |
Inhibiteurs du canal potassique médullaire externe rénal
|
|
US9265772B2
(en)
|
2012-05-11 |
2016-02-23 |
Reset Therapeutics, Inc. |
Carbazole-containing sulfonamides as cryptochrome modulators
|
|
AR092031A1
(es)
|
2012-07-26 |
2015-03-18 |
Merck Sharp & Dohme |
Inhibidores del canal de potasio medular externo renal
|
|
ES2786506T3
(es)
|
2012-08-01 |
2020-10-13 |
Zahra Tavakoli |
Composiciones congeladas fluidas que comprenden un agente terapéutico
|
|
EP2925322B1
(fr)
|
2012-11-29 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Inhibiteurs du canal potassique médullaire extérieur rénal
|
|
US9717714B2
(en)
|
2012-12-19 |
2017-08-01 |
Merck Sharp & Dohme Corp. |
Spirocyclic CETP inhibitors
|
|
US9725452B2
(en)
|
2013-03-15 |
2017-08-08 |
Presidents And Fellows Of Harvard College |
Substituted indoles and pyrroles as RIP kinase inhibitors
|
|
EP3079701B1
(fr)
|
2013-12-11 |
2021-08-11 |
Merck Sharp & Dohme Corp. |
Activateurs solubles de guanylate cyclase
|
|
EP3079700B1
(fr)
|
2013-12-11 |
2020-11-25 |
Merck Sharp & Dohme Corp. |
Activateurs solubles de guanylate cyclase
|
|
EP3083573B1
(fr)
|
2013-12-18 |
2024-08-07 |
Merck Sharp & Dohme LLC |
Inhibiteurs du canal potassique médullaire externe rénal
|
|
TWI690521B
(zh)
|
2014-04-07 |
2020-04-11 |
美商同步製藥公司 |
作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
|
|
US10590485B2
(en)
|
2014-05-29 |
2020-03-17 |
Geneticure Llc |
Therapeutic regimen for hypertension
|
|
WO2016018729A1
(fr)
|
2014-07-29 |
2016-02-04 |
Merck Sharp & Dohme Corp. |
Isoxazolines monocycliques utilisées comme inhibiteurs de la protéine de transfert des esters de cholestérol
|
|
PL3212226T3
(pl)
|
2014-10-31 |
2020-11-02 |
Ngm Biopharmaceuticals, Inc. |
Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych
|
|
TW201625635A
(zh)
|
2014-11-21 |
2016-07-16 |
默沙東藥廠 |
作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
|
|
EP3303342B1
(fr)
|
2015-05-27 |
2021-03-17 |
Merck Sharp & Dohme Corp. |
Dérivés d'imidazo-pyrazinyle utiles à titre d'activateurs de guanylate cyclase solubles
|
|
WO2016191335A1
(fr)
|
2015-05-28 |
2016-12-01 |
Merck Sharp & Dohme Corp. |
Dérivés d'imidazo-pyrazinyle utiles à titre d'activateurs de guanylate cyclase solubles
|
|
EP3322420B1
(fr)
|
2015-07-13 |
2021-12-29 |
Merck Sharp & Dohme Corp. |
Hétérocycles bicycliques en tant qu'inhibiteurs de la protéine de transfert des esters de cholestérol
|
|
WO2017107052A1
(fr)
|
2015-12-22 |
2017-06-29 |
Merck Sharp & Dohme Corp. |
Activateurs solubles de guanylate cyclase
|
|
WO2017197555A1
(fr)
|
2016-05-16 |
2017-11-23 |
Merck Sharp & Dohme Corp. |
Dérivés de pyrazine fusionnés utiles en tant que stimulateurs de la guanylate cyclase soluble
|
|
WO2020236688A1
(fr)
|
2019-05-22 |
2020-11-26 |
Merck Sharp & Dohme Corp. |
Agonistes du récepteur a du peptide natriurétique utiles pour le traitement de maladies cardiométaboliques, d'une maladie rénale et du diabète
|
|
EP3972589B1
(fr)
|
2019-05-22 |
2024-07-03 |
Merck Sharp & Dohme LLC |
Agonistes du récepteur du peptide natriurétique a utiles pour le traitement de maladies cardiométaboliques, de maladies rénales et du diabète
|
|
CN116133660B
(zh)
|
2020-07-22 |
2025-05-02 |
詹森药业有限公司 |
可用作因子XIa抑制剂的化合物
|
|
US11919881B2
(en)
|
2021-03-18 |
2024-03-05 |
Janssen Pharmaceutica Nv |
Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
|
|
US11814364B2
(en)
|
2021-03-18 |
2023-11-14 |
Janssen Pharmaceutica Nv |
Pyridine N-oxide derivatives useful as factor XIa inhibitors
|
|
US11845748B2
(en)
|
2021-03-18 |
2023-12-19 |
Janssen Pharmaceutica Nv |
Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
|
|
US11897880B2
(en)
|
2021-04-30 |
2024-02-13 |
Janssen Pharmaceutica Nv |
7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
|
|
US12286429B2
(en)
|
2021-07-22 |
2025-04-29 |
Janssen Pharmaceutica Nv |
5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors
|
|
US11958856B2
(en)
|
2021-07-22 |
2024-04-16 |
Janssen Pharmaceutica Nv |
Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
|